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Risk Factors for Heart Failure in Patients With Chronic Kidney
Disease: The CRIC (Chronic Renal Insufﬁciency Cohort) Study
Jiang He, MD, PhD; Michael Shlipak, MD, MPH; Amanda Anderson, PhD, MPH; Jason A. Roy, PhD; Harold I. Feldman, MD, MSCE;
Radhakrishna Reddy Kallem, MD; Radhika Kanthety, MD, MPH; John W. Kusek, PhD; Akinlolu Ojo, MD, PhD; Mahboob Rahman, MD;
Ana C. Ricardo, MD, MPH; Elsayed Z. Soliman, MD; Myles Wolf, MD, MMSc; Xiaoming Zhang, MS; Dominic Raj, MD; Lee Hamm, MD; for the
CRIC (Chronic Renal Insufﬁciency Cohort) Investigators*

Background-—Heart failure is common in patients with chronic kidney disease. We studied risk factors for incident heart failure
among 3557 participants in the CRIC (Chronic Renal Insufﬁciency Cohort) Study.
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Methods and Results-—Kidney function was assessed by estimated glomerular ﬁltration rate (eGFR) using serum creatinine,
cystatin C, or both, and 24-hour urine albumin excretion. During an average of 6.3 years of follow-up, 452 participants developed
incident heart failure. After adjustment for age, sex, race, and clinical site, hazard ratio (95% CI) for heart failure associated with 1
SD lower creatinine-based eGFR was 1.67 (1.49, 1.89), 1 SD lower cystatin C-based-eGFR was 2.43 (2.10, 2.80), and 1 SD higher
log-albuminuria was 1.65 (1.53, 1.78), all P<0.001. When all 3 kidney function measures were simultaneously included in the
model, lower cystatin C-based eGFR and higher log-albuminuria remained signiﬁcantly and directly associated with incidence of
heart failure. After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09,
1.72, P=0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, P=0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, P<0.001),
interleukin-6 (1.15, 95% CI 1.05, 1.25, P=0.002), and tumor necrosis factor-a (1.10, 95% CI 1.00, 1.21, P=0.05) were all
signiﬁcantly and directly associated with incidence of heart failure.
Conclusions-—Our study indicates that cystatin C-based eGFR and albuminuria are better predictors for risk of heart failure
compared to creatinine-based eGFR. Furthermore, anemia, insulin resistance, inﬂammation, and poor glycemic control are
independent risk factors for the development of heart failure among patients with chronic kidney disease. ( J Am Heart Assoc.
2017;6:e005336. DOI: 10.1161/JAHA.116.005336.)
Key Words: albuminuria • chronic kidney disease • glomerular ﬁltration rate • heart failure • risk factor

C

ardiovascular disease (CVD) is the major cause of
premature death in patients with chronic kidney disease
(CKD).1 Several prospective cohort studies have documented
an increased risk of CVD, including heart failure, in patients
with CKD.2–4 For example, Dhingra and colleagues reported
that individuals with creatinine-based estimated glomerular

ﬁltration rate (eGFR) <60 mL/min per 1.73 m2 had a 2-fold
increased risk of heart failure compared with those with eGFR
≥60 in a cohort of 10 181 participants followed up for
10 years.3 Reduced creatinine-based eGFR and increased
proteinuria measured by dipstick were signiﬁcantly associated
with increased risk of heart failure in a population-based
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Study Participants
The CRIC (Chronic Renal Insufﬁciency Cohort) Study is an
ongoing multicenter cohort study among 3939 participants
who were enrolled between June 2003 and August 2008 from
7 clinical centers in the United States. The design of the study
and baseline characteristics of participants have been previously published.5 Brieﬂy, men and women were eligible for the
study if they were between 21 and 74 years of age with an
eGFR between 20 and 70 mL/min per 1.73 m2 depending
upon age (age 21–44, eGFR 20–70; age 45–64, eGFR 20–60;
and age 65–74, eGFR 20–50). Patients who previously
received dialysis for ≥1 month or a kidney transplant, and
those with glomerulonephritis requiring immunosuppression,
cirrhosis, polycystic kidney disease, or severe heart failure,
deﬁned as New York Heart Association class III or IV, were
excluded. For this analysis, we excluded 382 patients with a
self-reported history of physician-diagnosed heart failure.
Therefore, a total of 3557 participants were included in this
analysis.
The investigation conforms with the principles outlined in
the Declaration of Helsinki. Institutional review boards at all
participating institutions approved the study protocol, and all
participants provided written informed consent.

Baseline Measurements
A baseline medical history questionnaire was administered to
obtain information on demographic characteristics, lifestyle
risk factors, previous history of CVD, and use of medications.
Body weight, height, and waist circumference were measured
according to standard methods. Three seated blood pressure
(BP) measurements were obtained by trained and certiﬁed
staff after at least 5 minutes of quiet rest. Hypertension was
deﬁned as mean BP ≥140/90 mm Hg or self-reported use of
antihypertensive medication.
DOI: 10.1161/JAHA.116.005336

Serum creatinine was measured using an enzymatic
method on an Ortho Vitros 950 and standardized to
isotope-dilution mass spectrometry traceable values. Cystatin
C, homocysteine, high-sensitive C-reactive protein, interleukin-6, and tumor necrosis factor (TNF)-a were measured
by the particle-enhanced immunonephelometry method. Fibrinogen was measured using the immunochemical reaction
method. eGFR was calculated according to the CKD-EPI
(Chronic Kidney Disease Epidemiology Collaboration) creatinine equation, cystatin C equation, and creatinine-cystatin C
equation.6 A homeostasis model assessment (HOMA) was
calculated to evaluate insulin resistance using fasting serum
insulin and plasma glucose.7 Diabetes mellitus was deﬁned as
a fasting plasma glucose ≥126 mg/dL, a nonfasting plasma
glucose ≥200 mg/dL, or self-reported use of anti-diabetes
mellitus medication. A 24-hour urine specimen was collected
in all participants and urinary albumin was measured by
radioimmunoassay. All laboratory measurements were conducted at the CRIC Study central laboratory at the University
of Pennsylvania with stringent quality control.

Assessment of Outcomes
CRIC Study participants were followed annually by clinic visits
with interim telephone contact at 6 months. The primary
study outcome was incident heart failure over the time from
study entry to March 2012. Heart failure was identiﬁed by
asking study participants every 6 months if they were
hospitalized, and selected hospitals or healthcare systems
were queried for qualifying encounters. The ﬁrst 30 discharge
codes were identiﬁed for all hospitalizations, and codes
relevant to heart failure resulted in retrieval of medical
records by study personnel for centralized adjudicated review.
At least 2 study physicians reviewed all possible heart failure
events using medical records and guidelines on clinical
symptoms, radiographic evidence of pulmonary congestion,
physical examination of the heart and lungs and, when
available, central venous hemodynamic monitoring data, and
echocardiographic imaging. Heart failure was conﬁrmed when
both reviewers agreed on a probable or deﬁnite occurrence of
heart failure based on modiﬁed clinical Framingham criteria.8
Patients’ follow-up was censored at the time of heart failure,
death, withdrawal, loss to follow-up, or the end of the followup period, whichever occurred ﬁrst.

Statistical Analysis
To compare the relative strengths in predicting incident heart
failure, hazard ratios associated with 1 SD of creatinine-based
eGFR, cystatin-C-based eGFR, or log-transformed albuminuria
were assessed using Cox proportional hazards models after
adjustment for age, sex, race, and clinical site.9 In addition,
Journal of the American Heart Association
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longitudinal study with 1 526 437 patients identiﬁed from
province-wide laboratory data from Alberta, Canada.4 However, the association of severity of CKD measured by
creatinine-based eGFR, cystatin C-based eGFR, and 24-hour
urine albumin with heart failure has not been well examined
among patients with CKD. In addition, the contribution of
novel CVD risk factors to the excess risk of heart failure
among patients with CKD has not been well investigated.
We aimed to compare the strengths of associations among
creatinine-based eGFR, cystatin C-based eGFR, and 24-hour
urine albumin and incident heart failure. In addition, we
investigated the association of traditional and novel CVD risk
factors with heart failure in patients with CKD.

Risk Factors for Heart Failure
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Results
Baseline characteristics of study participants by quartile of
creatinine and cystatin C-based eGFR are presented in
Table 1. Participants with lower creatinine and cystatin Cbased eGFR were more likely to be older, female, and black or
Hispanic; to have less than high school education and lower
physical activity and alcohol consumption, but higher current
smoking; to have higher prevalence of CVD, hypertension,
diabetes mellitus, and anemia; to have higher levels of body
mass index, waist circumference, systolic BP, HOMA-insulin
resistance, hemoglobin A1c (HbA1c), homocysteine, ﬁbrinogen, high-sensitive C-reactive protein, interleukin-6, TNF-a,
and leukocyte count, and lower levels of high-density
lipoprotein- and low-density lipoprotein-cholesterol, and
hemoglobin.
Over 6.3 years of follow-up, the overall incidence of heart
failure was 21.7 per 1000 person-years. In general, the
incidence of heart failure was higher among individuals with
lower creatinine-based eGFR and cystatin C-based eGFR
(Figure A). However, this association was more consistent
with cystatin C-based eGFR, especially among those with a
creatinine-based eGFR less than 60 mL/min per 1.73 m2.
Likewise, the incidence of heart failure was higher among
individuals with lower creatinine-based eGFR and higher
albuminuria (Figure B). This association was more consistent
with albuminuria.
DOI: 10.1161/JAHA.116.005336

The descriptive statistics of creatinine-based eGFR, cystatin C-based eGFR, and urine albumin, as well as their
correlation coefﬁcients, are shown in Table 2. As anticipated,
creatinine-based eGFR and cystatin C-based eGFR are highly
correlated. All 3 measures of CKD were associated with
incident heart failure after adjusting for age, sex, race, and
clinical site (Table 3). In the multivariable model including
both creatinine-based eGFR and cystatin C-based eGFR
simultaneously, the association between lower cystatin Cbased eGFR and heart failure became stronger, while the
association between lower creatinine-based eGFR and heart
failure became inverse. In multivariable models including both
creatinine-based eGFR and albuminuria, or cystatin C-based
eGFR and albuminuria, the associations of creatinine-based
eGFR, cystatin C-based eGFR, and albuminuria with incident
heart failure remained signiﬁcant. In multivariable models
including creatinine-based eGFR, cystatin C-based eGFR, and
albuminuria simultaneously, the associations of cystatin Cbased eGFR and albuminuria with incident heart failure
remained signiﬁcant, while the association between creatinine-based eGFR and heart failure became inverse.
After adjusting for age, sex, race, and clinical site, several
risk factors (ie, <high school education, history of CVD,
hypertension, and diabetes mellitus, higher levels of body
mass index, waist girth, systolic BP, cystatin C, and urine
albumin, and lower level of creatinine-cystatin C-based eGFR)
were signiﬁcantly associated with higher incidence of heart
failure. Higher levels of physical activity, alcohol consumption,
and high-density lipoprotein-cholesterol were signiﬁcantly
associated with lower incidence of heart failure (Table 4). In
the backward selection model, lesss than high school
education, history of CVD and diabetes mellitus, higher levels
of waist circumference, systolic BP, cystatin C, and urine
albumin remained signiﬁcantly associated with higher risk of
incident heart failure.
In the demographic-adjusted model, anemia, HOMA-insulin
resistance, HbA1c, uric acid, homocysteine, ﬁbrinogen, highsensitive C-reactive protein, interleukin-6, TNF-a, and leukocyte count were signiﬁcantly associated with increased risk of
incident heart failure while blood hemoglobin was signiﬁcantly
associated with decreased risk of incident heart failure
(Table 5). After further adjustment for the signiﬁcant traditional risk factors listed above, the associations of anemia,
hemoglobin, HOMA-insulin resistance, HbA1c, interleukin-6,
and TNF-a remained signiﬁcantly associated with higher risk
of incident heart failure.

Discussion
Our study indicated that the incidence of heart failure is high
in patients with CKD. Incident heart failure was signiﬁcantly
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these CKD markers were included in the multivariable Cox
proportional hazards models simultaneously. Age, sex, and
race were only moderately correlated with eGFR (r≤0.2) in the
CRIC participants. The assumption of proportionality was
tested using Schoenfeld residuals and interaction terms with
time for each exposure variable and covariate. No substantial
deviations from proportionality were observed.
The associations of baseline traditional and novel risk
factors with subsequent heart failure incidence were examined using multivariable Cox proportional hazards models.
Initial models were adjusted for age, sex, race, and clinical
site. For the multivariable analysis of traditional risk factors,
the backward elimination method was used, and only
covariates that were signiﬁcant (P<0.05) were retained in
the ﬁnal model. For the multivariable analysis of novel risk
factors, all variables retained in the ﬁnal traditional risk factor
model were included as covariates. The log-transformation
was performed for risk factors that were not normally
distributed. Hazard ratios and 95% CI of heart failure
associated with categorical variables or 1 SD increase in
continuous variables were presented. All analyses were
conducted using SAS version 9.1 (SAS Institute Inc, Cary,
NC). All P-values were 2-sided, and statistical signiﬁcance was
deﬁned as P<0.05.
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Table 1. Baseline Characteristics of Study Participants by Categories of Creatinine-Cystatin C-Based eGFR: the CRIC Study
Quartiles of eGFRCr─Cyst

C

(mL/min Per 1.73 m2)

≥60 (n=672)

45 to 59 (n=1021)

30 to 44 (n=1192)

<30 (n=672)

P-Values for
Group Differences

Age, mean (SD), y

53.2 (10.7)

58.8 (10.6)

59.6 (11.1)

58.2 (11.2)

<0.001

Male, n (%)

373 (55.5)

606 (59.4)

629 (52.8)

333 (49.6)

<0.001

White

357 (53.1)

471 (46.1)

476 (39.9)

217 (32.3)

<0.001

Black

239 (35.6)

398 (39.0)

505 (42.4)

291 (43.3)

Hispanic

38 (5.7)

110 (10.8)

173 (14.5)

139 (20.7)

Other

38 (5.7)

42 (4.1)

38 (3.2)

25 (3.7)

624 (93.0)

850 (83.3)

887 (74.4)

463 (68.9)

<0.001

Physical activity, mean (SD), MET/week

242.3 (165.7)

202.3 (129.9)

193.9 (152.2)

177.3 (136.9)

<0.001

Current cigarette smoking, n (%)

65 (9.7)

115 (11.3)

162 (13.6)

121 (18.0)

<0.001

Current alcohol consumption, n (%)

515 (76.6)

682 (66.8)

720 (60.4)

361 (53.7)

<0.001

Race/ethnicity, n (%)

High school education, n (%)
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History of cardiovascular disease, n (%)

92 (13.7)

260 (25.5)

360 (30.2)

222 (33.0)

<0.001

Hypertension, n (%)

435 (64.7)

904 (88.5)

1083 (90.9)

622 (92.6)

<0.001

Diabetes mellitus, n (%)

184 (27.4)

447 (43.8)

632 (53.0)

382 (56.8)

<0.001

Anemia*, n (%)

139 (20.8)

382 (37.6)

653 (55.1)

471 (70.4)

<0.001

Body mass index, mean (SD), kg/m2

30.2 (6.5)

31.8 (7.6)

32.6 (7.9)

32.4 (8.5)

<0.001

Waist circumference, mean (SD), cm

100.9 (15.1)

105.9 (17.4)

106.8 (17.5)

106.4 (18.7)

<0.001

Systolic blood pressure, mean (SD), mm Hg

121.6 (18.5)

127.2 (20.6)

130.6 (22.8)

133.5 (24.0)

<0.001

HDL-cholesterol, mean (SD), mg/dL

50.9 (16.8)

48.1 (15.2)

47.4 (15.7)

45.6 (14.4)

<0.001

LDL-cholesterol, mean (SD), mg/dL

108.4 (32.2)

104.7 (34.6)

101.7 (35.3)

101.9 (39.4)

<0.001

Hemoglobin, mean (SD), g/dL

13.6 (1.5)

13.0 (1.7)

12.3 (1.6)

11.7 (1.7)

<0.001

HOMA-insulin resistance, median (IQR)

3.17 (2.11, 5.39)

4.12 (2.64, 7.02)

4.22 (2.60, 7.45)

4.40 (2.57, 7.60)

<0.001

Hemoglobin A1c, mean (SD), %

6.19 (1.38)

6.57 (1.50)

6.76 (1.54)

6.73 (1.60)

<0.001

Uric acid, mean (SD), mg/dL

6.12 (1.61)

7.06 (1.69)

7.68 (1.73)

8.28 (1.96)

<0.001

Homocysteine, median (IQR), mg/dL

10.2 (8.6, 12.6)

12.8 (10.7, 15.3)

15.0 (12.5, 18.3)

17.8 (14.5, 22.0)

<0.001

Fibrinogen, mean (SD), mg/dL

3.51 (0.85)

3.96 (1.03)

4.29 (1.20)

4.71 (1.37)

<0.001

hsC-reactive protein, median (IQR), mg/L

1.51 (0.79, 3.59)

2.58 (1.10, 6.00)

2.89 (1.16, 7.10)

2.95 (1.11, 7.59)

<0.001

Interleukin-6, median (IQR), pg/mL

1.09 (0.71, 1.82)

1.67 (1.10, 2.60)

2.08 (1.34, 3.34)

2.59 (1.64, 4.13)

<0.001

Tumor necrosis factor-a, median (IQR), ng/mL

1.4 (1.0, 2.0)

1.9 (1.4, 2.7)

2.4 (1.8, 3.4)

3.2 (2.3, 4.2)

<0.001

Leukocyte count, median (IQR), 109 cells/L

5.6 (4.7, 6.8)

6.1 (5.1, 7.4)

6.4 (5.3, 7.8)

6.7 (5.6, 8.1)

<0.001

Creatinine, mean (SD), mg/dL

1.19 (0.21)

1.44 (0.22)

1.80 (0.33)

2.55 (0.58)

<0.001

Cystatin C, mean (SD), mg/L

0.89 (0.14)

1.20 (0.15)

1.60 (0.22)

2.31 (0.42)

<0.001

Urine albumin, median (IQR), g/24 h

0.01 (0.01, 0.05)

0.03 (0.01, 0.27)

0.11 (0.02, 0.80)

0.39 (0.06, 1.54)

<0.001

Mean (SD), median (interquartile range), or number (percent). CRIC indicates Chronic Renal Insufﬁciency Cohort Study; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular ﬁltration
rate; HDL, high-density lipoprotein; hsC-reactive protein, high-sensitive C-reactive protein; HOMA, homeostasis model assessment; IQR, interquartile range; LDL, low-density lipoprotein;
MET, metabolic equivalent of task.
*Anemia was deﬁned as hemoglobin <13 g/dL for men and <12 g/dL for women.

higher among patients with lower eGFR and higher albuminuria. Cystatin C-based eGFR and albuminuria were stronger
predictors for subsequent risk of heart failure than creatininebased eGFR among patients with CKD. In addition to
DOI: 10.1161/JAHA.116.005336

traditional risk factors, anemia, HOMA-insulin resistance,
HbA1c, interleukin-6, and TNF-a were signiﬁcantly associated
with increased risk of incident heart failure among patients
with CKD.
Journal of the American Heart Association
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Event rate, per 1,000 person-years

B

70.0
60.0
50.0
40.0
30.0
20.0

<30
30-44

10.0

45-59

0.0
≥1000

300-999

≥60
30-299

<30

Figure. Incidence of heart failure among patients with chronic
kidney disease by creatinine-based eGFR, cystatin C-based eGFR,
and 24-hour urine albumin: the CRIC (Chronic Renal Insufﬁciency
Cohort) Study. A, Incidence of heart failure by creatinine-based
eGFR and cystatin C-based eGFR; (B) Incidence of heart failure by
creatinine-based eGFR and albuminuria. eGFR indicates estimated
glomerular ﬁltration rate.
These ﬁndings have important clinical signiﬁcance because
CKD is highly prevalent in the general population and CVD,
including heart failure, is the leading cause of death among
patients with CKD.1 In the Framingham Heart Study, the
incidence of heart failure was 4.7 per 1000 person-years
among 3757 men and 4472 women aged 40 to 94 years who
were followed up from 1971 to 1996.10 The Cardiovascular
Lifetime Risk Pooling Project included 39 578 adults aged
45 years and older from 3 US cohort studies and reported a
heart failure incidence of 8.3 per 1000 person-years.11 In the
Multi-Ethnic Study of Atherosclerosis study, the incidence of
heart failure was 3.1 per 1000 person-years among 6814
participants aged 45 to 84 years.12 The incidence of heart
failure in our study participants is much higher than in these
studies conducted in the general population but similar to
studies in CKD populations.13 For example, the incidence of
DOI: 10.1161/JAHA.116.005336

heart failure was 23 per 1000 person-years in a communitybased cohort of 114 900 adults with CKD stages 3 to 4 in
Northern California.13 Our study documented a several-fold
increased incidence of heart failure among patients with CKD
relative to the general population.
In the Chronic Kidney Disease Prognosis Consortium
cohorts, decreased creatinine-based eGFR and increased
urinary albumin-to-creatinine ratio were independently associated with all-cause and CVD mortality.1 Blecker and
colleagues reported that albuminuria was associated with
subsequent risk of heart failure in the Atherosclerosis Risk in
Communities Study.14 In addition, decreased cystatin C-based
eGFR and albuminuria independently contributed to the risk of
heart failure in the Atherosclerosis Risk in Communities
study.2 The independent associations of decreased creatininebased eGFR and increased urinary albumin-to-creatinine ratio
with incident heart failure were also observed in a large
population-based longitudinal study in Alberta, Canada.4 Our
study indicated that creatinine-based eGFR, cystatin C-based
eGFR, and albuminuria are all associated with incident heart
failure. However, when all 3 CKD measures were included in
the same model simultaneously, cystatin C-based eGFR and
albuminuria provided better prediction of incident heart
failure. It has been suggested in previous studies that cystatin
C improves the prediction of CVD mortality beyond creatinine.15 Our study also indicated that the association between
lower creatinine-based eGFR and heart failure became inverse
after adjustment for cystatin C-based eGFR. There are 2
alternate explanations for this ﬁnding. First, it is possible that
high multicollinearity between cystatin C-based eGFR and
creatinine-based eGFR results in a change of sign of the
regression parameter estimate for the latter. Second, after
adjustment for more precise GFR measurement (cystatin Cbased eGFR), non-GFR determinants of serum creatinine (ie,
muscle mass and nutritional status) were associated with
lower all-cause mortality and heart failure incidence.16,17
Our study found that less than a high school education,
history of CVD, diabetes mellitus, systolic BP, and waist
circumference were signiﬁcantly and independently associated with increased risk of heart failure. These traditional risk
factors have been associated with increased risk of heart
failure among the general population in previous cohort
studies.18
Anemia is common among patients with CKD and is
associated with increased risk of CVD in this population.19,20
In addition, anemia is frequent among patients with heart
failure and is associated with adverse outcomes and high
mortality among these patients.20 Our study indicated that
baseline anemia is a signiﬁcant and independent risk factor
for subsequent risk of heart failure among patients with CKD.
Furthermore, there is an inverse association between blood
hemoglobin level and incidence of heart failure. However,
Journal of the American Heart Association
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Risk Factors for Heart Failure

Correlation Coefﬁcients (P-Values)

Mean (SD)

Media (IQR)

Creatinine-Based
eGFR

Cystatin C-Based eGFR

Creatinine-based eGFR,
mL/min per 1.73 m2

44.9 (15.1)

43.8 (33.5, 54.7)

1.00

0.826 (<0.001)

0.202 (<0.001)

0.265 (<0.001)

Cystatin C-based eGFR,
mL/min per 1.73 m2

53.3 (23.7)

48.9 (35.3, 67.5)

1.00

0.242 (<0.001)

0.314 (<0.001)

Albuminuria, g/24 h

0.68 (1.59)

0.06 (0.01, 0.55)

Log-albuminuria, g/24 h*

0.33 (0.52)

0.06 (0.01, 0.44)

Albuminuria

1.00

Log-Albuminuria

0.924 (<0.001)
1.00

Creatinine-based eGFR ranged from 6.9 to 110.4 mL/min per 1.73 m2; cystatin C-based eGFR ranged from 11.1 to 150.0 mL/min per 1.73 m2; albuminuria ranged from 0 to 18.5 g/
24 h; and log-albuminuria ranged from 0 to 2.97 g/24 h. eGFR indicates estimated glomerular ﬁltration rate; IQR, interquartile range.
*Log-albuminuria=Log (urine albumin g/24 h+1).
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several clinical trials have shown that treatment of anemia
among patients with CKD does not reduce CVD outcomes,
including heart failure.21–23 Anemia could be a comorbid
condition or common underlying cause of CKD and heart
failure.24,25 Future studies should examine whether the
prevention of anemia in patients with CKD will reduce the
risk of incident heart failure.
Inﬂammatory biomarkers have been associated with
increased risk of heart failure in community-based cohort
studies.26,27 Our study provides novel ﬁndings on the
association between systemic inﬂammation and risk of

heart failure among patients with CKD. After adjustment for
age, sex, and race, it was determined that multiple
inﬂammatory biomarkers, including ﬁbrinogen, high-sensitive
C-reactive protein, interleukin-6, TNF-a, and leukocyte
count, were all signiﬁcantly associated with incident heart
failure. After additional adjustment for established CVD risk
factors, interleukin-6 and TNF-a were signiﬁcantly and
independently associated with risk of heart failure. These
data suggest that inﬂammation might play an important
role in the development of heart failure among patients
with CKD.

Table 3. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With 1 SD of Creatinine-Based
eGFR, Cystatin C-Based eGFR, and Log-Transformed 24-Hour Urine Albumin
Hazard Ratio (95% CI)

P-Value

Age, sex, and race adjusted

1.67 (1.49, 1.89)

<0.001

Age, sex, race, and cystatin C-based eGFR adjusted

0.78 (0.65, 0.93)

0.006

Age, sex, race, and urine albumin adjusted

1.40 (1.23, 1.59)

<0.001

Age, sex, race, cystatin C-based eGFR, and urine albumin adjusted

0.77 (0.65, 0.92)

0.005

Age, sex, and race adjusted

2.43 (2.10, 2.80)

<0.001

Age, sex, race, and creatinine-based eGFR adjusted

3.04 (2.45, 3.78)

<0.001

Age, sex, race, and urine albumin adjusted

2.01 (1.73, 2.34)

<0.001

Age, sex, race, creatinine-based eGFR, and urine albumin adjusted

2.52 (2.02, 3.15)

<0.001

Age, sex, and race adjusted

1.65 (1.53, 1.78)

<0.001

Age, sex, race, and creatinine-based eGFR adjusted

1.56 (1.44, 1.69)

<0.001

Age, sex, race, and cystatin C-based eGFR adjusted

1.45 (1.34, 1.58)

<0.001

Age, sex, race, creatinine-based eGFR, and cystatin C-based eGFR adjusted

1.45 (1.34, 1.58)

<0.001

1 SD decrease in creatinine-based eGFR ( 15.1 mL/min 1.73 m2)

1 SD decrease in cystatin C-based eGFR ( 23.8 mL/min)

1 SD increase in log-albuminuria (0.5 g/24 h)

All analyses stratiﬁed by clinical site. eGFR indicates estimated glomerular ﬁltration rate; log-albuminuria, log (urine albumin g/24 h+1).
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Table 2. Descriptive Statistics and Correlation Coefﬁcients of Creatinine-Based eGFR, Cystatin C-Based eGFR, and 24-Hour Urine
Albumin

Risk Factors for Heart Failure

He et al

Multivariable-Adjusted†

Age-Sex-Race-Adjusted
Variables*

Hazard Ratio (95% CI)

P-Value

Hazard Ratio (95% CI)

P-Value

<High-school education

1.75 (1.39, 2.19)

<0.001

1.47 (1.15, 1.87)

0.002

Physical activity, 147.5 MET/week

0.80 (0.71, 0.90)

<0.001

Current cigarette smoking

1.24 (0.95, 1.62)

0.11

Current alcohol consumption

0.75 (0.61, 0.91)

0.003

History of cardiovascular disease

4.72 (3.89, 5.73)

<0.001

3.28 (2.67, 4.04)

<0.001

Hypertension

2.85 (1.80, 4.50)

<0.001

3.04 (2.46, 3.76)

<0.001

1.71 (1.35, 2.16)

<0.001

Body mass index, 7.7 kg/m

1.35 (1.24, 1.47)

<0.001

Waist circumference, 17.4 cm

1.42 (1.30, 1.56)

<0.001

1.28 (1.16, 1.42)

<0.001

Systolic blood pressure, 22 mm Hg

1.45 (1.33, 1.58)

<0.001

1.23 (1.10, 1.36)

<0.001

HDL-cholesterol, 15.6 mg/dL

0.81 (0.72, 0.91)

<0.001

LDL-cholesterol, 35.5 mg/dL

0.96 (0.87, 1.05)

0.36

Cystatin C, 0.5 mg/dL

1.73 (1.60, 1.88)

<0.001

1.42 (1.29, 1.56)

<0.001

1.65 (1.53, 1.78)

<0.001

1.22 (1.11, 1.34)

<0.001

2.08 (1.83, 2.37)

<0.001

Diabetes mellitus
2
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Log urine albumin, 0.5 g/24 h
eGFRCr─Cyst C,

2

16.9 mL/min 1.73 m

All analyses stratiﬁed by clinical site. CVD indicates cardiovascular disease; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular ﬁltration rate; HDL, high-density lipoprotein; LDL,
low-density lipoprotein; MET, metabolic equivalent of task.
*Binary variable or 1 SD.
†
Multivariable model was selected by the backward selection method.

The association between diabetes mellitus and heart
failure has been well described, with diabetes mellitus
increasing the risk of heart failure by 2- to 6-fold.28 Recent

population-based cohort studies reported that insulin resistance, calculated from insulin and glucose, was associated
with increased risk of heart failure.29,30 Our study indicates

Table 5. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With Novel CVD Risk Factors
Multivariable-Adjusted†

Age-Sex-Race Adjusted
Variables*

Hazard Ratio (95% CI)

P-Value

Hazard Ratio (95% CI)

P-Value

Anemia

2.19 (1.79, 2.69)

<0.001

1.37 (1.09, 1.72)

0.006

Blood hemoglobin, 1.8 g/dL

0.61 (0.55, 0.68)

<0.001

0.85 (0.75, 0.96)

0.007

Log HOMA-insulin resistance, 0.67 unit

1.41 (1.29, 1.53)

<0.001

1.16 (1.04, 1.28)

0.006

Hemoglobin A1c, 1.5%

1.54 (1.43, 1.65)

<0.001

1.27 (1.14, 1.41)

<0.001

Uric acid, 1.9 mg/dL

1.21 (1.09, 1.33)

<0.001

1.05 (0.94, 1.17)

0.37

Log homocysteine, 0.33 mg/dL

1.23 (1.11, 1.36)

<0.001

0.90 (0.79, 1.03)

0.11

Fibrinogen, 1.2 mg/dL

1.55 (1.42, 1.68)

<0.001

1.06 (0.95, 1.18)

0.30

Log hsC-reactive protein, 0.87 mg/L

1.18 (1.08, 1.29)

<0.001

1.07 (0.97, 1.18)

0.20

Log interleukin-6, 0.66 pg/mL

1.30 (1.22, 1.39)

<0.001

1.15 (1.05, 1.25)

0.002

Log tumor necrosis factor-a, 0.50 ng/mL

1.27 (1.18, 1.36)

<0.001

1.10 (1.00, 1.21)

0.05

Log leukocyte count, 0.269109 cells/L

1.28 (1.17, 1.40)

<0.001

1.07 (0.97, 1.19)

0.17

All analyses stratiﬁed by clinical site. CVD indicates cardiovascular disease; eGFRCr─Cyst C, creatinine and cystatin C-based glomerular ﬁltration rate; HOMA, homeostasis model
assessment; hsC-reactive protein, high-sensitive C-reactive protein.
*Binary variable or 1 SD.
†
Adjusted for age, sex, race, education, history of cardiovascular disease, diabetes mellitus, systolic blood pressure, waist circumference, serum cystatin C, log-urine albumin, and
eGFRCr─Cyst C.
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Table 4. Multivariable-Adjusted Hazard Ratios (95% CI) of Congestive Heart Failure Associated With Established CVD Risk Factors

Risk Factors for Heart Failure
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